Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ethics and ego dissolution: the case of psilocybin
William Smith, Dominic A. Sisti
Journal of Medical Ethics (2020) Vol. 47, Iss. 12, pp. 807-814
Open Access | Times Cited: 102

Showing 1-25 of 102 citing articles:

The Therapeutic Potential of Psilocybin
Henry Lowe, Ngeh J. Toyang, Blair Steele, et al.
Molecules (2021) Vol. 26, Iss. 10, pp. 2948-2948
Open Access | Times Cited: 153
Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials
Jacob S. Aday, Boris D. Heifets, Steven D. Pratscher, et al.
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1989-2010
Open Access | Times Cited: 146
Racial Justice Requires Ending the War on Drugs
Brian D. Earp, Jonathan Lewis, Carl L. Hart
The American Journal of Bioethics (2021) Vol. 21, Iss. 4, pp. 4-19
Open Access | Times Cited: 114
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
Michiel van Elk, David B. Yaden
Neuroscience & Biobehavioral Reviews (2022) Vol. 140, pp. 104793-104793
Open Access | Times Cited: 106
Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default
David B. Yaden, Dylan Earp, Marianna Graziosi, et al.
Frontiers in Psychology (2022) Vol. 13
Open Access | Times Cited: 76
Distinctive But Not Exceptional: The Risks of Psychedelic Ethical Exceptionalism
Katherine Cheung, Brian D. Earp, Kyle Patch, et al.
The American Journal of Bioethics (2025) Vol. 25, Iss. 1, pp. 16-28
Closed Access | Times Cited: 14
Novel ethical and policy issues in psychiatric uses of psychedelic substances
William Smith, Paul S. Appelbaum
Neuropharmacology (2022) Vol. 216, pp. 109165-109165
Open Access | Times Cited: 40
Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry
Gregory Barber, Charles C. Dike
Psychiatric Services (2023) Vol. 74, Iss. 8, pp. 838-846
Closed Access | Times Cited: 37
Transformative experience and informed consent to psychedelic-assisted psychotherapy
Edward Jacobs
Frontiers in Psychology (2023) Vol. 14
Open Access | Times Cited: 28
Giving Consent to the Ineffable
Daniel Villiger
Neuroethics (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 10
Toward a Broader Psychedelic Bioethics
Edward Jacobs, David B. Yaden, Brian D. Earp
AJOB Neuroscience (2023) Vol. 14, Iss. 2, pp. 126-129
Open Access | Times Cited: 19
Psychedelic unselfing: self-transcendence and change of values in psychedelic experiences
Juuso Kähönen
Frontiers in Psychology (2023) Vol. 14
Open Access | Times Cited: 17
With great power comes great vulnerability: an ethical analysis of psychedelics’ therapeutic mechanisms proposed by the REBUS hypothesis
Daniel Villiger, Manuel Trachsel
Journal of Medical Ethics (2023) Vol. 49, Iss. 12, pp. 826-832
Open Access | Times Cited: 16
Informed Consent to Psychedelic-Assisted Psychotherapy: Ethical Considerations
Andrew G. Lee, Daniel Rosenbaum, Daniel Z. Buchman
The Canadian Journal of Psychiatry (2024) Vol. 69, Iss. 5, pp. 309-313
Open Access | Times Cited: 7
Psychedelic Therapy as Form of Life
Nicolas Langlitz, Alex K. Gearin
Neuroethics (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 7
Navigating Groundlessness: An interview study on dealing with ontological shock and existential distress following psychedelic experiences
Eirini K. Argyri, Jules Evans, David Luke, et al.
SSRN Electronic Journal (2024)
Closed Access | Times Cited: 7
Psychedelic Experiences Increase Mind Perception but do not Change Atheist-Believer Status: A Prospective Longitudinal Study
Sandeep M. Nayak, Sydney H. White, Samantha Hilbert, et al.
Journal of Psychoactive Drugs (2024), pp. 1-10
Closed Access | Times Cited: 6
Psilocybin for the treatment of Alzheimer’s disease
Siyi Zheng, Rong Ma, Yang Yang, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 6
A Transformative Trip? Experiences of Psychedelic Use
Logan Neitzke‐Spruill, Caroline Beit, Jill O. Robinson, et al.
Neuroethics (2024) Vol. 17, Iss. 2
Open Access | Times Cited: 5
Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022
Xuepeng Jing, Nicholas Hoeh, David B Menkes
Palliative & Supportive Care (2023) Vol. 21, Iss. 4, pp. 697-704
Open Access | Times Cited: 14
Informed Consent to Psychedelic Treatment—A Work in Progress
Paul S. Appelbaum
JAMA Psychiatry (2024) Vol. 81, Iss. 6, pp. 543-543
Closed Access | Times Cited: 5
Personal psychedelic experience of psychedelic therapists during training: should it be required, optional, or prohibited?
Daniel Villiger
International Review of Psychiatry (2024), pp. 1-10
Open Access | Times Cited: 5
Informed Consent Under Ignorance
Daniel Villiger
The American Journal of Bioethics (2024), pp. 1-13
Open Access | Times Cited: 4
Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper
Marianne Destoop, Pavel Mohr, Florence Butlen-Ducuing, et al.
European Psychiatry (2025) Vol. 68, Iss. 1
Open Access
Excusing Psychedelics and Accommodating Psychedelics
Edward Jacobs
The American Journal of Bioethics (2025) Vol. 25, Iss. 1, pp. 107-109
Open Access
Page 1 - Next Page

Scroll to top